• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMU
Click for more information
5.41% 3.9¢

IMUGENE LIMITED - Announcements

Market Cap $386.7M  ! watchlist Created with Sketch. Add to my watchlist

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
IMU Change of Director's Interest Notice (AH)02/11/15
IMU Change of Director's Interest Notice (OB)30/10/15
IMU Change of Director's Interest Notice (CW)30/10/15
IMU Ceasing to be a substantial holder28/10/15
IMU Appendix 4C - quarterlyPRICE SENSITIVE28/10/15
IMU Imugene Receives $755k R&D Tax RefundPRICE SENSITIVE28/10/15
IMU Appendix 3B and Section 708A Notice26/10/15
IMU Letter to Option Holders23/10/15
IMU Prospectus for Placement & Loyalty OptionsPRICE SENSITIVE23/10/15
IMU Appendix 3B - Loyalty Option Issue23/10/15
IMU Results of Meeting15/10/15
IMU AGM Corporate Presentation15/10/15
IMU Imugene announces bonus options issuePRICE SENSITIVE13/10/15
IMU Notice of Annual General Meeting/Proxy Form14/09/15
IMU Corporate Presentation08/09/15
IMU Imugene Announces Successful Capital RaisingPRICE SENSITIVE08/09/15
IMU Trading HaltPRICE SENSITIVE07/09/15
IMU Summary of Full Year Results31/08/15
IMU Appendix 4G31/08/15
IMU Appendix 4E and Annual Report 2015PRICE SENSITIVE31/08/15
IMU Immuno-oncology Specialist Appointed Chief Operating Officer27/08/15
IMU Appendix 4C - quarterlyPRICE SENSITIVE30/07/15
IMU Change of Share Registry24/07/15
IMU New Research Note available from Edison Investment Research13/07/15
IMU CRO Appointed to Conduct Phase 1b/2 Gastric Cancer TrialPRICE SENSITIVE01/07/15
IMU Proposed Issue of Options to Dr Axel Hoos29/06/15
IMU Change of Share Registry Address12/06/15
IMU Prof Ursula Wiedermann Appointed Chief Scientific Officer05/06/15
IMU HER-Vaxx superior to Herceptin in tumour modelPRICE SENSITIVE22/05/15
IMU Appendix 4C - quarterlyPRICE SENSITIVE29/04/15
IMU Imugene Files New HER-Vaxx PatentPRICE SENSITIVE21/04/15
IMU News Update and Corporate Presentation20/04/15
IMU HER-Vaxx Re-Formulation Increases Efficacy Ten-FoldPRICE SENSITIVE20/04/15
IMU New Research Note available from Edison Investment Research14/04/15
IMU Investor Presentation24/03/15
IMU Investor Presentation10/03/15
IMU Imugene to Present at 27th Annual Roth Conference06/03/15
IMU Grant of Options to Dr Nick Ede & Appendix 3B27/02/15
IMU Appendix 4D - Half Yearly Report and AccountsPRICE SENSITIVE27/02/15
IMU Summary of Half Year results27/02/15
IMU Response to Price QueryPRICE SENSITIVE20/02/15
IMU Imugene Receives $230K Research and Development Tax RefundPRICE SENSITIVE18/02/15
IMU Investor Presentation10/02/15
IMU Initial Director's Interest Notice02/02/15
IMU Appointment of Charles Walker as Managing DirectorPRICE SENSITIVE02/02/15
IMU Appendix 4C - quarterlyPRICE SENSITIVE28/01/15
IMU Investor Presentation13/01/15
IMU Appendix 3B06/01/15
IMU New milestones in preparation for HER-Vaxx clinical trialPRICE SENSITIVE30/12/14
IMU Notice under section 708A of the Corporations Act18/12/14
IMU Ceasing to be a substantial holder16/12/14
IMU Ceasing to be a substantial holder16/12/14
IMU Change in substantial holding16/12/14
IMU Ceasing to be a substantial holder16/12/14
IMU Change of Director's Interest Notice (PH)16/12/14
IMU Change of Director's Interest Notice (OB)16/12/14
IMU Completion of share purchase plan allotment16/12/14
IMU Appendix 3B15/12/14
IMU Further placement & close of SPP raising over $3.5m in totalPRICE SENSITIVE09/12/14
IMU Release of Shares from Escrow05/12/14
IMU New Research Note available from Edison Investment Research04/12/14
IMU HER-Vaxx peptides demonstrate high level of activityPRICE SENSITIVE01/12/14
IMU Publication of Research Note28/11/14
IMU Imugene to divest Linguet drug delivery technologyPRICE SENSITIVE28/11/14
IMU Extension of Share Purchase Plan Closing Date27/11/14
IMU Results of Meeting25/11/14
IMU AGM 2014 Presentation25/11/14
IMU Placement Cleansing Notice13/11/14
IMU Additional placement details12/11/14
IMU Appendix 3B12/11/14
IMU Share Purchase Plan Offer Document & Cleansing Notice07/11/14
IMU Correction to Record Date of Share Purchase Plan05/11/14
IMU Capital raising for clinical development of HER-VaxxPRICE SENSITIVE05/11/14
IMU Share Purchase Plan Cleansing Notice05/11/14
IMU Investor Presentation05/11/14
IMU Trading HaltPRICE SENSITIVE03/11/14
IMU Appendix 4C - quarterlyPRICE SENSITIVE31/10/14
IMU Notice of Annual General Meeting/Proxy Form24/10/14
IMU Annual Report to shareholders24/10/14
IMU Resignation of Director23/10/14
IMU Investor Presentation21/10/14
IMU Imugene HER-Vaxx patent granted in USPRICE SENSITIVE08/10/14
IMU Investor Presentation16/09/14
IMU Swiss Drug Manufacturer to Speed Her-Vaxx DevelopmentPRICE SENSITIVE15/09/14
IMU Research Agreement with Medical University of ViennaPRICE SENSITIVE08/09/14
IMU Appendix 4E and Annual Financial ReportPRICE SENSITIVE28/08/14
IMU Investor Newsletter28/08/14
IMU Charles Walker appointed Imugene CEOPRICE SENSITIVE26/08/14
IMU HER-Vaxx patent application receives US Notice of AllowancePRICE SENSITIVE29/07/14
IMU Appendix 4C - quarterlyPRICE SENSITIVE25/07/14
IMU Mymetics Engaged to Manufacture HER-VaxxPRICE SENSITIVE16/07/14
IMU Initial Director's Interest Notice08/07/14
IMU Otto Buttula appointed Non-Executive Director07/07/14
IMU Investor Update11/06/14
IMUImugene Commences Manufacture of its Gastric Cancer VaccinePRICE SENSITIVE27/05/14
IMUChange in substantial holding05/05/14
IMUAppendix 4C - quarterlyPRICE SENSITIVE23/04/14
IMUGastric cancer specialist joins Imugene SAB23/04/14
IMUChange of Director's Interest Notice (NE)17/04/14
IMUImugene Allowed Israel Patent for Cancer VaccinePRICE SENSITIVE24/03/14
IMU Change of Director's Interest Notice (AH)
02/11/15
IMU Change of Director's Interest Notice (OB)
30/10/15
IMU Change of Director's Interest Notice (CW)
30/10/15
IMU Ceasing to be a substantial holder
28/10/15
IMU Appendix 4C - quarterly
28/10/15PRICE SENSITIVE
IMU Imugene Receives $755k R&D Tax Refund
28/10/15PRICE SENSITIVE
IMU Appendix 3B and Section 708A Notice
26/10/15
IMU Letter to Option Holders
23/10/15
IMU Prospectus for Placement & Loyalty Options
23/10/15PRICE SENSITIVE
IMU Appendix 3B - Loyalty Option Issue
23/10/15
IMU Results of Meeting
15/10/15
IMU AGM Corporate Presentation
15/10/15
IMU Imugene announces bonus options issue
13/10/15PRICE SENSITIVE
IMU Notice of Annual General Meeting/Proxy Form
14/09/15
IMU Corporate Presentation
08/09/15
IMU Imugene Announces Successful Capital Raising
08/09/15PRICE SENSITIVE
IMU Trading Halt
07/09/15PRICE SENSITIVE
IMU Summary of Full Year Results
31/08/15
IMU Appendix 4G
31/08/15
IMU Appendix 4E and Annual Report 2015
31/08/15PRICE SENSITIVE
IMU Immuno-oncology Specialist Appointed Chief Operating Officer
27/08/15
IMU Appendix 4C - quarterly
30/07/15PRICE SENSITIVE
IMU Change of Share Registry
24/07/15
IMU New Research Note available from Edison Investment Research
13/07/15
IMU CRO Appointed to Conduct Phase 1b/2 Gastric Cancer Trial
01/07/15PRICE SENSITIVE
IMU Proposed Issue of Options to Dr Axel Hoos
29/06/15
IMU Change of Share Registry Address
12/06/15
IMU Prof Ursula Wiedermann Appointed Chief Scientific Officer
05/06/15
IMU HER-Vaxx superior to Herceptin in tumour model
22/05/15PRICE SENSITIVE
IMU Appendix 4C - quarterly
29/04/15PRICE SENSITIVE
IMU Imugene Files New HER-Vaxx Patent
21/04/15PRICE SENSITIVE
IMU News Update and Corporate Presentation
20/04/15
IMU HER-Vaxx Re-Formulation Increases Efficacy Ten-Fold
20/04/15PRICE SENSITIVE
IMU New Research Note available from Edison Investment Research
14/04/15
IMU Investor Presentation
24/03/15
IMU Investor Presentation
10/03/15
IMU Imugene to Present at 27th Annual Roth Conference
06/03/15
IMU Grant of Options to Dr Nick Ede & Appendix 3B
27/02/15
IMU Appendix 4D - Half Yearly Report and Accounts
27/02/15PRICE SENSITIVE
IMU Summary of Half Year results
27/02/15
IMU Response to Price Query
20/02/15PRICE SENSITIVE
IMU Imugene Receives $230K Research and Development Tax Refund
18/02/15PRICE SENSITIVE
IMU Investor Presentation
10/02/15
IMU Initial Director's Interest Notice
02/02/15
IMU Appointment of Charles Walker as Managing Director
02/02/15PRICE SENSITIVE
IMU Appendix 4C - quarterly
28/01/15PRICE SENSITIVE
IMU Investor Presentation
13/01/15
IMU Appendix 3B
06/01/15
IMU New milestones in preparation for HER-Vaxx clinical trial
30/12/14PRICE SENSITIVE
IMU Notice under section 708A of the Corporations Act
18/12/14
IMU Ceasing to be a substantial holder
16/12/14
IMU Ceasing to be a substantial holder
16/12/14
IMU Change in substantial holding
16/12/14
IMU Ceasing to be a substantial holder
16/12/14
IMU Change of Director's Interest Notice (PH)
16/12/14
IMU Change of Director's Interest Notice (OB)
16/12/14
IMU Completion of share purchase plan allotment
16/12/14
IMU Appendix 3B
15/12/14
IMU Further placement & close of SPP raising over $3.5m in total
09/12/14PRICE SENSITIVE
IMU Release of Shares from Escrow
05/12/14
IMU New Research Note available from Edison Investment Research
04/12/14
IMU HER-Vaxx peptides demonstrate high level of activity
01/12/14PRICE SENSITIVE
IMU Publication of Research Note
28/11/14
IMU Imugene to divest Linguet drug delivery technology
28/11/14PRICE SENSITIVE
IMU Extension of Share Purchase Plan Closing Date
27/11/14
IMU Results of Meeting
25/11/14
IMU AGM 2014 Presentation
25/11/14
IMU Placement Cleansing Notice
13/11/14
IMU Additional placement details
12/11/14
IMU Appendix 3B
12/11/14
IMU Share Purchase Plan Offer Document & Cleansing Notice
07/11/14
IMU Correction to Record Date of Share Purchase Plan
05/11/14
IMU Capital raising for clinical development of HER-Vaxx
05/11/14PRICE SENSITIVE
IMU Share Purchase Plan Cleansing Notice
05/11/14
IMU Investor Presentation
05/11/14
IMU Trading Halt
03/11/14PRICE SENSITIVE
IMU Appendix 4C - quarterly
31/10/14PRICE SENSITIVE
IMU Notice of Annual General Meeting/Proxy Form
24/10/14
IMU Annual Report to shareholders
24/10/14
IMU Resignation of Director
23/10/14
IMU Investor Presentation
21/10/14
IMU Imugene HER-Vaxx patent granted in US
08/10/14PRICE SENSITIVE
IMU Investor Presentation
16/09/14
IMU Swiss Drug Manufacturer to Speed Her-Vaxx Development
15/09/14PRICE SENSITIVE
IMU Research Agreement with Medical University of Vienna
08/09/14PRICE SENSITIVE
IMU Appendix 4E and Annual Financial Report
28/08/14PRICE SENSITIVE
IMU Investor Newsletter
28/08/14
IMU Charles Walker appointed Imugene CEO
26/08/14PRICE SENSITIVE
IMU HER-Vaxx patent application receives US Notice of Allowance
29/07/14PRICE SENSITIVE
IMU Appendix 4C - quarterly
25/07/14PRICE SENSITIVE
IMU Mymetics Engaged to Manufacture HER-Vaxx
16/07/14PRICE SENSITIVE
IMU Initial Director's Interest Notice
08/07/14
IMU Otto Buttula appointed Non-Executive Director
07/07/14
IMU Investor Update
11/06/14
IMUImugene Commences Manufacture of its Gastric Cancer Vaccine
27/05/14PRICE SENSITIVE
IMUChange in substantial holding
05/05/14
IMUAppendix 4C - quarterly
23/04/14PRICE SENSITIVE
IMUGastric cancer specialist joins Imugene SAB
23/04/14
IMUChange of Director's Interest Notice (NE)
17/04/14
IMUImugene Allowed Israel Patent for Cancer Vaccine
24/03/14PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
3.9¢ 		Change
0.002(5.41%) 		Mkt cap ! $386.7M
Open High Low Value Volume
3.6¢ 4.0¢ 3.5¢ $1.163M 31.27M

Buyers (Bids)

No. Vol. Price($)
6 2275218 3.8¢
 

Sellers (Offers)

Price($) Vol. No.
3.9¢ 196677 3
View Market Depth
Last trade - 16.10pm 22/11/2024 (20 minute delay) ?
Last
3.9¢ 		  Change
0.002 ( 5.41 %)
Open High Low Volume
3.6¢ 4.0¢ 3.6¢ 12995141
Last updated 15.59pm 22/11/2024 ?
IMU (ASX) Chart

Top Stories

HotCopper Highlights: Your most watched stocks for Week 47, 2024

In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing, through Week 47. Let’s get into it. 
Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in the hands of two industry giants. But what does this mean for Australians @ greater access to cheaper medicines or the loss of small, commun...
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL Welcome to the end of another week. Let's start with what HotCopper users have been watching and discussing.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.